ANK1

Across TCGA pan-cancer cohorts, ANK1 Mutation is linked to patient survival in 16 of 34 cancer types, making it a survival-associated ANK1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ANK1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANK1 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, ESCA, and ACC are the cancer types where ANK1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.948	0.636	.002	40	view →
ESCA	OS	Median	II,III,IV	0.266	0.711	<.001	36	view →
ACC	DFS	Median	All	0.120	0.772	<.001	30	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
UCEC	DFS	Median	II,III,IV	0.869	0.425	.013	16	view →
BLCA	OS	Median	II,III,IV	0.842	0.409	.013	16	view →
THYM	DFS	Median	All	0.075	0.885	<.001	12	view →
KIRC	OS	Median	All	0.249	0.805	.010	12	view →
PRAD	OS	Median	All	0.816	0.990	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	5	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

ANK1–STAD (DFS)

Open the STAD breakdown →